Viridian Therapeutics, Inc./DE Increase (Decrease) in Contract with Customer, Asset
Viridian Therapeutics, Inc./DE (VRDN) reported Increase (Decrease) in Contract with Customer, Asset of $70.00 million for the 9-month period ending 2025-09-30, per its 10-Q filed 2025-11-05.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInContractWithCustomerAsset · last filed 2025-11-05
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for the quarter ending 2025-09-30 was $70.00M, a 68527.45% increase year-over-year.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for the quarter ending 2024-12-31 was -$102.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for the quarter ending 2024-09-30 was $102.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for the quarter ending 2024-06-30 was -$102.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for fiscal 2024 was -$102.00K.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for fiscal 2023 was $0.00.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for fiscal 2022 was -$349.00K, a 177.38% decline from fiscal 2021.
- Viridian Therapeutics, Inc./DE increase (decrease) in contract with customer, asset for fiscal 2021 was $451.00K.
| Period end | Increase (Decrease) in Contract with Customer, Asset 3 month | Increase (Decrease) in Contract with Customer, Asset 3 month as first filed | Increase (Decrease) in Contract with Customer, Asset 6 month | Increase (Decrease) in Contract with Customer, Asset 9 month | Increase (Decrease) in Contract with Customer, Asset 9 month as first filed | Increase (Decrease) in Contract with Customer, Asset 12 month |
|---|---|---|---|---|---|---|
| 2025-09-30 | $70.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $70.00M 10-Q · filed 2025-11-05 | ||||
| 2025-06-30 | $0.00 10-Q · filed 2025-08-06 | |||||
| 2024-12-31 | -$102.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | -$102.00K derived: sum of 3 quarters · filed 2025-11-05 | -$102.00K 10-K · filed 2025-03-03 | ||
| 2024-09-30 | $102.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-05 | $0.00 derived: sum of 2 quarters · filed 2025-11-05 | $0.00 10-Q · filed 2025-11-05 | -$88.00K 10-Q · filed 2024-11-12 | $0.00 derived: sum of 4 quarters · filed 2025-11-05 | |
| 2024-06-30 | -$102.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-06 | -$102.00K 10-Q · filed 2025-08-06 | -$102.00K derived: sum of 3 quarters · filed 2025-08-06 | -$102.00K derived: sum of 4 quarters · filed 2025-08-06 | ||
| 2024-03-31 | $0.00 10-Q · filed 2024-05-08 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | $0.00 derived: sum of 3 quarters · filed 2025-03-03 | -$26.00K derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | $0.00 derived: sum of 2 quarters · filed 2025-03-03 | -$26.00K derived: sum of 3 quarters · filed 2025-03-03 | $0.00 10-K · filed 2025-03-03 | ||
| 2023-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-12 | -$26.00K derived: sum of 2 quarters · filed 2024-11-12 | $0.00 10-Q · filed 2024-11-12 | -$297.00K derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-06-30 | -$26.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-08 | $0.00 10-Q · filed 2024-08-08 | -$297.00K derived: sum of 3 quarters · filed 2025-03-03 | -$592.00K derived: sum of 4 quarters · filed 2025-03-03 | ||
| 2023-03-31 | $26.00K 10-Q · filed 2024-05-08 | $6.65M 10-Q · filed 2023-05-10 | -$271.00K derived: sum of 2 quarters · filed 2025-03-03 | -$566.00K derived: sum of 3 quarters · filed 2025-03-03 | -$394.00K derived: sum of 4 quarters · filed 2025-03-03 | |
| 2022-12-31 | -$297.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-03 | -$592.00K derived: sum of 2 quarters · filed 2025-03-03 | -$420.00K derived: sum of 3 quarters · filed 2025-03-03 | -$349.00K 10-K · filed 2025-03-03 | ||
| 2022-09-30 | -$295.00K derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-13 | -$123.00K derived: sum of 2 quarters · filed 2023-11-13 | -$52.00K 10-Q · filed 2023-11-13 | -$80.00K derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-06-30 | $172.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | $243.00K 10-Q · filed 2023-08-08 | $215.00K derived: sum of 3 quarters · filed 2024-02-27 | -$1.36M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2022-03-31 | $71.00K 10-Q · filed 2023-05-10 | $43.00K derived: sum of 2 quarters · filed 2024-02-27 | -$1.53M derived: sum of 3 quarters · filed 2024-02-27 | $1.90M derived: sum of 4 quarters · filed 2024-02-27 | ||
| 2021-12-31 | -$28.00K derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-27 | -$1.60M derived: sum of 2 quarters · filed 2024-02-27 | $1.83M derived: sum of 3 quarters · filed 2024-02-27 | $451.00K 10-K · filed 2024-02-27 | ||
| 2021-09-30 | -$1.57M derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-14 | $1.86M derived: sum of 2 quarters · filed 2022-11-14 | $479.00K 10-Q · filed 2022-11-14 | |||
| 2021-06-30 | $3.43M derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-15 | $2.05M 10-Q · filed 2022-08-15 | ||||
| 2021-03-31 | -$1.38M 10-Q · filed 2022-05-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Mineralys Therapeutics, Inc. (MLYS) | United States | $2.353B | -6.82 |
| Harmony Biosciences Holdings, Inc. (HRMY) | United States | $2.399B | 11.67 |
| Vera Therapeutics, Inc. (VERA) | United States | $2.402B | -7.67 |
| uniQure N.V. (QURE) | $2.416B | -4.93 | |
| SELLAS Life Sciences Group, Inc. (SLS) | United States | $2.420B | -91.87 |
| Zai Lab Ltd (ZLAB) | $2.241B | -113.34 | |
| Nurix Therapeutics, Inc. (NRIX) | United States | $2.457B | -5.39 |
| Aurinia Pharmaceuticals Inc. (AUPH) | $2.207B | 7.18 | |
| SUPERNUS PHARMACEUTICALS, INC. (SUPN) | United States | $2.517B | -24.63 |
| Prestige Consumer Healthcare Inc. (PBH) | United States | $2.163B | 13.03 |